The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy

@article{Roach2013TheRO,
  title={The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy},
  author={R E J Roach and Willem M Lijfering and Frans M. Helmerhorst and Suzanne C. Cannegieter and Frits Richard Rosendaal and Astrid van Hylckama Vlieg},
  journal={Journal of Thrombosis and Haemostasis},
  year={2013},
  volume={11}
}
Roach REJ, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013; 11: 124–31. 
How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?
TLDR
This review summarizes some important points about the selection of the safest hormonal replacement modality in women with a history of venous thromboembolism and management of VTE risks in postmenopausal women wishing to take HRT. Expand
Prevention and treatment of venous thromboembolism during HRT: current perspectives
  • H. Rott
  • Medicine
  • International journal of general medicine
  • 2014
TLDR
Bioidentical hormone therapy via the transdermal route seems to be the safest opportunity for hormone replacement therapy, although large trials for bioidentical hormones therapy are needed. Expand
Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta‐analysis
TLDR
The results support discouraging COC‐use in women with a natural anticoagulant deficiency and additive risk of factor V Leiden (FVL) or prothrombin‐G20210A (PT) mutation is modest. Expand
Venous thromboembolism in women: new challenges for an old disease
TLDR
A nonsystematic review of recent literature evaluating and summarizing the associations between VTE and clinical situations peculiar to women and evaluating the patients’ contraindications, eligibility criteria, and autonomy. Expand
Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?
TLDR
It is aimed to review the latest literature on the risk of initial and recurrent VTE with COC and HRT use to provide guidance for decision-making about duration of anticoagulation, and guide future research efforts. Expand
Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis.
TLDR
Clinicians are challenged to relieve menopausal symptoms without increasing the risk of thrombosis with transdermal therapies and with progesterone over synthetic progestogens (progestins). Expand
Hormones and venous thromboembolism among postmenopausal women
  • P. Scarabin
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2014
TLDR
There is strong evidence that VTE risk is greater in women using medroxyprogesterone acetate compared with those receiving other progestins, and progesterone appears safe with respect to VTE. Expand
The incidence and prognosis of thromboembolism associated with oral contraceptives: Age‐dependent difference in Japanese population
TLDR
The incidence and prognosis of thromboembolism associated with combined oral contraceptives (COCs) by age groups in Japan by agegroups in Japan is analyzed. Expand
Hormone therapy and risk of venous thromboembolism among postmenopausal women.
TLDR
Transdermal estrogens alone or combined with micronized progesterone may represent the safest alternative for women who require postmenopausal hormone therapy. Expand
Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
TLDR
VTE risk was increased in postmenopausal women with no previous thromboembolic events using oral HT, and further clinical trials are needed to sort out the impact of different types of progestin and different estrogen doses and administration routes on VTE risk. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Mechanisms of estrogen-induced venous thromboembolism.
TLDR
This review summarizes the current knowledge on the effects of different kinds of hormonal contraceptives on haemostatic variables and the relationship between the changes of these variable and the risk of venous thrombosis. Expand
Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study
TLDR
Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women using hormone therapy and route of estrogen administration and concomitant progestogens type are 2 important determinants of thrombotic risk. Expand
Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study
TLDR
Oral but not transdermal estrogen is associated with an increased VTE risk, and data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect toThrombotic risk. Expand
Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study
TLDR
In contrast to oral estrogen, transdermal estrogen does not confer an additional risk of idiopathic VTE in women with increased BMI, and the safety of transDermal estrogen on thrombotic risk has to be confirmed. Expand
Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease
TLDR
If factor V Leiden genotyping becomes less expensive, it could be cost effective to screen for the presence of the mutation before instituting HRT in women with coronary disease. Expand
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
TLDR
Recalculation of population incidences shows that the absolute risk of venous thrombosis in young women who use oral contraceptives is much larger when they carry the factor V Leiden mutation. Expand
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
TLDR
A high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives is confirmed, and many women do not use the safest brands. Expand
Estrogen plus progestin and risk of venous thrombosis.
TLDR
Estrogen plus progestin therapy was associated with doubling the risk of venous thrombosis and the risks associated with age, overweight or obesity, and factor V Leiden were increased. Expand
Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis
TLDR
It is concluded that the thrombosis risk of HRT may particularly affect women with prothrombotic mutations, and efforts to avoid HRT in women with increased risk of thromBosis are advisable. Expand
Postmenopausal Estrogen Replacement and Risk for Venous Thromboembolism
TLDR
The venous thromboembolism risk with postmenopausal estrogen replacement therapy is estimated using a meta-analysis of eligible studies and fixed-effects and random-effects models using the Bayesian data analytic framework. Expand
...
1
2
3
4
...